Our annual report for 2020 has been published

Wed Mar 24 2021

Our annual report for 2020 has just been published

In 2020, we made promising progress despite the challenging circumstances caused by the COVID-19 pandemic.

We have been able to establish a more robust platform with more clinical routine customers across all suPARnostic® products and have increased our revenue by 49%.

Our company demonstrated that the European strategy and investments in the commercial efforts are working.

“In 2020, we saw the first results of our investments in the commercialization of the suPARnostic® products. Despite significant setbacks in traditional sales activities due to the pandemic, we managed to grow our revenue. We shifted our focus towards online selling and early identified the potential of using suPAR as a biomarker for triaging COVID-19 patients. As a result, we welcomed new clinical routine customers in several markets.”

– Jakob Knudsen, CEO of ViroGates

Business highlights in 2020

  • Announced six new clinical routine hospital customers, including four from Spain
  • Received the first order from a private health clinic in Sweden
  • Announced collaboration with Interlux Group to market suPARnostic® products in the Baltic countries
  • Validated and obtained CE-IVD approval for suPARnostic® TurbiLatex on Siemens Healthineers ADVIA® XPT Chemical Diagnostics System and Abbott Labs Architect Clinical Chemistry Platform
  • Awarded a 6.6 DKKm EU Horizon 2020 grant for a project to optimize hospital resources and ensure early therapeutic intervention for COVID-19 patients based on suPARnostic®
  • Announced two capital increases in connection with the exercise of warrants
  • Updated the strategic objective to become cash flow positive with the existing cash at hand
  • Received and handled a customer complaint regarding suPARnostic® ELISA

Please find the full report here

Annual Report 2020


published suPAR studies in leading medical journals

Nature Medicine Logo
Science Journal Logo
JAMA Pediatrics Logo

The suPARnostic® brand consists of 3 products:

Quick Triage

A Point of Care Solution


For Automated Systems


Clinical and Research

suPAR is used in clinical routine in 48 hospitals

48 hospitals use suPAR in clinical routine for triage of patients in the Emergency Departments and COVID-19 units. Clinical routine is defined by the placement of two Purchasing Orders within the last 12 months rolling.
This period covers January 1, 2022, until December 31, 2022. Some hospital locations cannot be disclosed due to confidentiality.

New Webinar


Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates